21
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:November 15, 2022Approved for marketing
Refractory Multiple Myeloma: 1443 Clinical Trials, Page 3 of 145
Hide Studies Not Open or Pending
22
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma
Condition(s):Relapsed and Refractory Multiple MyelomaLast Updated:December 17, 2020Completed
23
A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:January 18, 2023Recruiting
24
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:February 11, 2022Recruiting
25
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Condition(s):Refractory Multiple Myeloma; Relapse Multiple MyelomaLast Updated:August 19, 2020Withdrawn
26
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:January 25, 2023Recruiting
27
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:May 26, 2022Recruiting
28
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
Condition(s):Relapsed and/or Refractory Multiple MyelomaLast Updated:August 4, 2022Not yet recruiting
29
A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:November 2, 2021Active, not recruiting
30
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
Condition(s):Multiple MyelomaLast Updated:December 21, 2022Completed